Micro3: Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors

Sponsor
Centre Hospitalier Universitaire de Saint Etienne (Other)
Overall Status
Completed
CT.gov ID
NCT06046144
Collaborator
(none)
161
1
5.9
27.2

Study Details

Study Description

Brief Summary

Reflectance confocal microscopy (RCM) is the reference in vivo imaging technique for identifying malignant melanocytic tumors prior to surgical excision. However, it is not widely used due to its high cost and highly technical and time-consuming nature.

In addition to RCM, we currently use 2 less expensive dermatoscopes that also allow in vivo diagnosis: super-high magnification dermoscopy (D400) and Fluorescence-Advanced videodermatoscopy (FAV).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Fluorescence-Advanced videodermatoscopy
  • Diagnostic Test: Reflectance confocal microscopy
  • Diagnostic Test: Super-high magnification dermoscopy

Detailed Description

Several studies have demonstrated their interest in the in vivo diagnosis of melanocytic tumors, but without any comparison between these methods.

In our current practice, many patients have benefited from these 3 imaging modalities for benign and malignant lesions.

Therefore, our aim is to analyze these images and compare their performance in the diagnosis of benign and malignant pigmented lesions.

Study Design

Study Type:
Observational
Actual Enrollment :
161 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors. Monocentric Retrospective Study of 170 Tumors
Actual Study Start Date :
Nov 2, 2022
Actual Primary Completion Date :
May 1, 2023
Actual Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Patients with a pigmented skin lesion

Patients with a pigmented skin lesion of more than 3mm diameter which have benefited systematically of all 3 imaging techniques at the same time, followed by either a surgical excision or annual imaging monitoring.

Diagnostic Test: Fluorescence-Advanced videodermatoscopy
Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern. Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.

Diagnostic Test: Reflectance confocal microscopy
Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern. Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.

Diagnostic Test: Super-high magnification dermoscopy
Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern. Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.

Outcome Measures

Primary Outcome Measures

  1. To analyse the picture to assess the relevance of each technique for the diagnostic of malignant and benign pigmented lesions. [Day 1]

    The nature of the tumor is diagnosed by an imaging technique if we can find on the images the main characteristics belonging to a certain tumor. After this we can calculate the sensitivity, specificity of each technique.

Secondary Outcome Measures

  1. Comparison of different imaging techniques [Day 1]

    To compare the performance of combination of 2 techniques to assess if the performance is better than 1 technique alone.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with a pigmented skin lesion of more than 3mm diameter which have benefited systematically of all 3 imaging techniques at the same time, followed by either a surgical excision or annual imaging monitoring.
Exclusion Criteria:
  • Bad quality images

  • Insufficient number of images

  • Uncertain diagnosis given by the pathologist

  • Refusal

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chu de Saint Etienne Saint Etienne France 42000

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

Investigators

  • Principal Investigator: Jean-Luc PERROT, MD PhD, CHU Saint-Etienne

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT06046144
Other Study ID Numbers:
  • IRBN1142023/CHUSTE
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023